Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...1415161718192021222324...208209»
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
    New trial:  PTC-Guided Therapy for Peritoneal Mesothelioma (clinicaltrials.gov) -  Jan 10, 2026   
    P=N/A,  N=347, Recruiting, 
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Journal:  Shenling Baizhu powder alleviates Pyrotinib-induced diarrhea via CFTR-activated chloride secretion. (Pubmed Central) -  Jan 8, 2026   
    In addition to confirming its therapeutic effect, this study reveals a previously unrecognized mechanism whereby SBP downregulates EGFR-dependent CFTR activation, offering a mechanistic explanation for its antidiarrheal properties. These findings not only highlight the mechanistic novelty of SBP in the context of targeted-therapy-associated diarrhea but also provide a scientific foundation supporting its clinical application and future translational development.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer (clinicaltrials.gov) -  Jan 7, 2026   
    P2/3,  N=113, Active, not recruiting, 
    These findings not only highlight the mechanistic novelty of SBP in the context of targeted-therapy-associated diarrhea but also provide a scientific foundation supporting its clinical application and future translational development. Not yet recruiting --> Active, not recruiting | N=280 --> 113 | Trial completion date: Mar 2024 --> Dec 2026 | Trial primary completion date: Mar 2022 --> Dec 2026
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, HEOR, Real-world evidence:  A Real World Study of ?2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Jan 6, 2026   
    P=N/A,  N=59, Completed, 
    Most PSA50 responses occurred during BAT, and responders showed favorable outcomes with subsequent therapy, possibly reflecting restoraion in sensitivity to ADT and improvement in immune infiltration. Recruiting --> Completed | N=100 --> 59 | Trial completion date: Aug 2024 --> Nov 2025 | Trial primary completion date: Aug 2024 --> Oct 2025
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, vinorelbine tartrate / Generic mfg.
    Retrospective data, Journal, Real-world evidence:  Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study. (Pubmed Central) -  Jan 5, 2026   
    The most frequently concomitant targeted drug was pyrotinib (70/90,77.8%)...Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  Severe systemic cutaneous adverse reactions following camrelizumab therapy: a case report and literature review. (Pubmed Central) -  Jan 5, 2026   
    This case highlights the importance of recognizing camrelizumab-associated dermatologic toxicity, emphasizes the role of timely corticosteroid intervention, and suggests that cautious rechallenge may be feasible in selected patients. Further investigation is warranted to elucidate the immunopathological mechanisms underlying severe skin reactions to PD-1 inhibitors and to optimize prevention and management strategies.
  • ||||||||||  Review, Journal:  Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. (Pubmed Central) -  Jan 5, 2026   
    It focuses on elaborating the research breakthroughs of URAT1 inhibitor derivatives and the new drug SHR4640...At the same time, it details the action pathways and clinical evidence of emerging therapies such as SGLT2 inhibitors, the GLP-1/GCG dual-receptor agonist Mazdutide, probiotics, and washed microbiota transplantation (WMT). By summarizing mechanistic insights, clinical progress, and translational prospects, this review aims to inform the development of individualized and integrative therapeutic strategies for hyperuricemia.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, irinotecan / Generic mfg.
    Journal:  The cytoskeletal protein smoothelin maintains homologous recombination repair by stabilizing RAD51 in an HUWE1-dependent manner in colorectal cancer. (Pubmed Central) -  Jan 1, 2026   
    To explore the therapeutic role of SMTN, customized cell membrane infused biomimetic liposomes were constructed to ensure rapid delivery of SMTN siRNA specifically into HCT-116 cells, yielding significantly enhanced anti-cancer effects of irinotecan and fuzuloparib both in vitro and in vivo. To summarize, our findings revealed a novel function of SMTN in DNA damage repair and provided a therapeutic strategy of targeting SMTN to enhance the efficacy of DNA damage agents.
  • ||||||||||  zeprumetostat (SHR-2554) / Treeline Biosci, AiTan (rivoceranib) / HLB Bio Group, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    New P2 trial:  SHR-1701 + Rivoceranib ( (clinicaltrials.gov) -  Dec 31, 2025   
    P2,  N=40, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma. (Pubmed Central) -  Dec 26, 2025   
    Post-embolization symptoms occurred only in the TACE group but no grade 3-4 events were observed, and rates of systemic treatment-related adverse events were comparable between groups. Adding TACE to rivoceranib-camrelizumab has the potential to improve tumor response and survival in BCLC stage C HCC without compromising safety.